Clinical Trial: GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07673666) titled 'GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)' on June 23.

Brief Summary: The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Astro23 can help detect a specific molecular type of brain tumour called IDH mutant Astrocytoma (grade 2 and 3) using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA).

The main questions it aims to answer are:

* How accurately can GliomaAI-Astro23 identify IDH mutant Astrocytoma (grade 2 and 3) from MRI scan...